BR112012024936A2 - uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo - Google Patents

uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo

Info

Publication number
BR112012024936A2
BR112012024936A2 BR112012024936A BR112012024936A BR112012024936A2 BR 112012024936 A2 BR112012024936 A2 BR 112012024936A2 BR 112012024936 A BR112012024936 A BR 112012024936A BR 112012024936 A BR112012024936 A BR 112012024936A BR 112012024936 A2 BR112012024936 A2 BR 112012024936A2
Authority
BR
Brazil
Prior art keywords
diacerein
methods
prodrug
analogue
pharmaceutically acceptable
Prior art date
Application number
BR112012024936A
Other languages
English (en)
Inventor
Chih-Ming Chen
Danchen Gao
I-Yin Lin
Mannching Sherry Ku
Wei-Shu Lu
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of BR112012024936A2 publication Critical patent/BR112012024936A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos de um tratamento adjunto e de um tratamento de combinação para o diabetes melito, método para melhorar controle glicêmico em um indivíduos, e, métodos para reduzir um efeito colateral e um risco cardiovasculares de um agente antidiabético a presente invenção fornece métodos de tratar o diabetes tipo ii usando combinações de diacereína ou seus derivados com outros agentes antidiabéticos. os métodos também podem permitir melhorar controle glicêmico de pacientes com o diabetes tipo ii e/ou reduzir os feitos colaterais e/ou riscos cardiovasculares de agentes antidiabéticos.
BR112012024936A 2010-04-08 2011-04-07 uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo BR112012024936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32193110P 2010-04-08 2010-04-08
PCT/US2011/031517 WO2011127240A1 (en) 2010-04-08 2011-04-07 Methods of using diacerein as an adjunctive therapy for diabetes

Publications (1)

Publication Number Publication Date
BR112012024936A2 true BR112012024936A2 (pt) 2015-09-15

Family

ID=44761380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024936A BR112012024936A2 (pt) 2010-04-08 2011-04-07 uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo

Country Status (16)

Country Link
US (1) US8536152B2 (pt)
EP (1) EP2555618B1 (pt)
JP (2) JP6085552B2 (pt)
KR (1) KR101567925B1 (pt)
CN (1) CN102858155B (pt)
AU (1) AU2011237600B2 (pt)
BR (1) BR112012024936A2 (pt)
CA (1) CA2794566C (pt)
ES (1) ES2560310T3 (pt)
IL (1) IL222133A (pt)
MX (1) MX2012011517A (pt)
NZ (1) NZ602583A (pt)
PT (1) PT2555618E (pt)
RU (1) RU2563988C2 (pt)
TW (1) TWI519297B (pt)
WO (1) WO2011127240A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
CN101822660B (zh) * 2010-05-13 2013-07-10 中国人民解放军肾脏病研究所 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用
MX373702B (es) 2015-07-01 2020-05-07 Twi Biotechnology Inc Formulaciones topicas de diacereina o rheina y sus usos.
US10195170B2 (en) * 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1276781B1 (it) * 1995-06-23 1997-11-03 Gentili Ist Spa Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie
CN1086289C (zh) * 1997-09-30 2002-06-19 中国人民解放军肾脏病研究所 大黄酸或大黄酸盐在制备治疗糖尿病肾病药中的用途
AR026801A1 (es) * 2000-01-12 2003-02-26 Medidom Lab Sustancias para uso en el tratamiento de la psoriasis
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
CN1748675A (zh) * 2005-07-11 2006-03-22 丛晓东 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
JP2013502587A (ja) * 2009-08-20 2013-01-24 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド 糖尿病の診断および治療効果の決定方法
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
CN103429236B (zh) * 2011-03-11 2016-09-21 安成生物科技股份有限公司 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物

Also Published As

Publication number Publication date
TW201210586A (en) 2012-03-16
WO2011127240A1 (en) 2011-10-13
JP2013523832A (ja) 2013-06-17
AU2011237600A1 (en) 2012-10-11
CA2794566A1 (en) 2011-10-13
MX2012011517A (es) 2012-11-29
AU2011237600B2 (en) 2016-06-23
NZ602583A (en) 2014-10-31
RU2012147449A (ru) 2014-05-20
EP2555618A4 (en) 2013-11-13
US20110251155A1 (en) 2011-10-13
KR20130045266A (ko) 2013-05-03
KR101567925B1 (ko) 2015-11-10
CN102858155A (zh) 2013-01-02
RU2563988C2 (ru) 2015-09-27
JP2016041739A (ja) 2016-03-31
EP2555618A1 (en) 2013-02-13
TWI519297B (zh) 2016-02-01
CN102858155B (zh) 2015-02-04
IL222133A (en) 2017-01-31
ES2560310T3 (es) 2016-02-18
PT2555618E (pt) 2016-03-08
CA2794566C (en) 2018-06-12
US8536152B2 (en) 2013-09-17
JP6085552B2 (ja) 2017-02-22
EP2555618B1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
BR112013029062A2 (pt) lixisenatida e metformina para o tratamento de diabetes tipo 2
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
BR112012025017A2 (pt) métodos para melhorar a qualidade do sono.
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
WO2011127070A3 (en) IRE-1α INHIBITORS
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112014009785A8 (pt) método para tratar ou reduzir efp
MX2009013989A (es) Terapia en combinacion para depresion.
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
ECSP13012658A (es) Composiciones y métodos para el tratamiento de la mielofibrosis
BR112012002578B8 (pt) usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística
BR112013029256A2 (pt) &#34;combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina&#34;.
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
BR112012024936A2 (pt) uso de diacereína ou de um sal, um análogo, uma prodroga, ou um metabólito ativo farmaceuticamente aceitável do mesmo
UY33369A (es) Heterociclilbencil-pirazoles sustituidos y su uso
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112015022907A2 (pt) formas de sal de (2-(2-(4-fluorfenil)tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements